pulmonary alveolar proteinosis and alveolar microlithiasis. Wegeners granulomatosis is vasculitis that is associated with pulmonary manifestations in most of the cases. ILD: Interstitial lung disease.

offering a groundbreaking solution for diagnosing autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease. The test requires just a finger-prick blood sample and builds upon the ...

has announced the publication of a manuscript detailing long-term outcomes for molgramostim inhalation solution in patients ...

Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease that affects somewhere between 4 and 40 people per million worldwide. The condition causes substances such as fats and proteins ...

The sisters that Neehus studied had several lung abnormalities: a history of respiratory infections, polycystic lung disease, and pulmonary alveolar proteinosis (PAP), a disorder characterized by lung ...

for MOLBREEVI* as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP). If Priority Review is granted by the FDA, MOLBREEVI could potentially be approved by the end of the year.

His father had received a diagnosis of myelodysplastic syndrome at age 33 years and had died from pulmonary alveolar proteinosis and invasive pulmonary aspergillosis at age 36 years. Clinical images ...

Autoimmune pulmonary alveolar proteinosis is characterized by the accumulation of surfactant in the lungs, leading to difficulty in breathing and other severe symptoms. Current treatments are limited, ...

Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).